Abstract:Summary Background The options for first-line treatment of advanced oesophageal squamous cell carcinoma are scarce, and the outcomes remain poor. The anti-PD-1 antibody, tislelizumab, has shown antitumour activity in previously treated patients with advanced oesophageal squamous cell carcinoma. We report interim analysis results from the RATIONALE-306 study, which aimed to assess tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment for advanced or metastatic oesophageal squamous cell carcinoma. Methods This global, randomised, double-blind, parallel-arm, placebo-controlled, phase 3 study was conducted at 162 medical centres across Asia, Europe, Oceania, and North America. Patients (aged ≥18 years) with unresectable, locally advanced, recurrent or metastatic oesophageal squamous cell carcinoma (regardless of PD-L1 expression), Eastern Cooperative Oncology Group performance status of 0–1, and measurable or evaluable disease per Response Evaluation Criteria in Solid Tumours (version 1.1) were recruited. Patients were randomly assigned (1:1), using permuted block randomisation (block size of four) and stratified by investigator-chosen chemotherapy, region, and previous definitive therapy, to tislelizumab 200 mg or placebo intravenously every 3 weeks on day 1, together with an investigator-chosen chemotherapy doublet, comprising a platinum agent (cisplatin 60–80 mg/m 2 intravenously on day 1 or oxaliplatin 130 mg/m 2 intravenously on day 1) plus a fluoropyrimidine (fluorouracil [750–800 mg/m 2 intravenously on days 1–5] or capecitabine [1000 mg/m 2 orally twice daily on days 1–14]) or paclitaxel (175 mg/m 2 intravenously on day 1). Treatment was continued until disease progression or unacceptable toxicity. Investigators, patients, and sponsor staff or designees were masked to treatment. The primary endpoint was overall survival. The efficacy analysis was done in the intention-to-treat population (ie, all randomly assigned patients) and safety was assessed in all patients who received at least one dose of study treatment. The trial is registered with ClinicalTrials.gov , NCT03783442 . Findings Between Dec 12, 2018, and Nov 24, 2020, 869 patients were screened, of whom 649 were randomly assigned to tislelizumab plus chemotherapy (n=326) or placebo plus chemotherapy (n=323). Median age was 64·0 years (IQR 59·0–69·0), 563 (87%) of 649 participants were male, 86 (13%) were female, 486 (75%) were Asian, and 155 (24%) were White. 324 (99%) of 326 patients in the tislelizumab group and 321 (99%) of 323 in the placebo group received at least one dose of the study drug. As of data cutoff (Feb 28, 2022), median follow-up was 16·3 months (IQR 8·6–21·8) in the tislelizumab group and 9·8 months (IQR 5·8–19·0) in the placebo group, and 196 (60%) of 326 patients in the tislelizumab group versus 226 (70%) of 323 in the placebo group had died. Median overall survival in the tislelizumab group was 17·2 months (95% CI 15·8–20·1) and in the placebo group was 10·6 months (9·3–12·1; stratified hazard ratio 0·66 [95% CI 0·54–0·80]; one-sided p<0·0001). 313 (97%) of 324 patients in the tislelizumab group and 309 (96%) of 321 in the placebo group had treatment-related treatment-emergent adverse events. The most common grade 3 or 4 treatment-related treatment-emergent adverse events were decreased neutrophil count (99 [31%] in the tislelizumab group vs 105 [33%] in the placebo group), decreased white blood cell count (35 [11%] vs 50 [16%]), and anaemia (47 [15%] vs 41 [13%]). Six deaths in the tislelizumab group (gastrointestinal and upper gastrointestinal haemorrhage [n=2], myocarditis [n=1], pulmonary tuberculosis [n=1], electrolyte imbalance [n=1], and respiratory failure [n=1]) and four deaths in the placebo group (pneumonia [n=1], septic shock [n=1], and unspecified death [n=2]) were determined to be treatment-related. Interpretation Tislelizumab plus chemotherapy as a first-line treatment for advanced or metastatic oesophageal squamous cell carcinoma provided superior overall survival with a manageable safety profile versus placebo plus chemotherapy. Given that the interim analysis met its superiority boundary for the primary endpoint, as confirmed by the independent data monitoring committee, this Article represents the primary study analysis. Funding BeiGene.

Tislelizumab (TIS) Plus Chemotherapy (chemo) Vs Placebo (PBO) Plus Chemo As First-Line (1L) Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (GC/GEJC): Health-related Quality of Life (hrqol) Outcomes in the RATIONALE-305 Study.

137P Tislelizumab Combined with Chemotherapy As Neoadjuvant Therapy for Stage IIIA-IIIB(N2) Potentially Resectable Squamous Non-Small-cell Lung Cancer (TACT)

Rationale 305: Phase 3 study of tislelizumab plus chemotherapy vs placebo plus chemotherapy as first-line treatment (1L) of advanced gastric or gastroesophageal junction adenocarcinoma (GC/GEJC).

Abstract CT552: RATIONALE 304: Tislelizumab (TIS) Plus Chemotherapy Versus Chemotherapy Alone As First-Line (1L) Treatment for Non-Squamous (Non-Sq) NSCLC in Patients (pts) Aged 65-75 Years

P17.02 RATIONALE 307: A Subgroup Analysis of Tislelizumab Plus Chemo Vs Chemo Alone As 1L Treatment for Stage IIIB Advanced Sq NSCLC

Tislelizumab in Combination with Chemotherapy in Chinese Patients with Advanced Gastric or Gastroesophageal Junction (G/GEJ) Cancer: Results from One Cohort of an Ongoing Phase 2 Study.

85P Phase II Trial of Tislelizumab Plus Sitravatinib As Maintenance Therapy in Extensive-Stage Small-Cell Lung Cancer (ES-SCLC)

1297P RATIONALE 307: Tislelizumab (TIS) Plus Chemotherapy (chemo) Vs Chemo Alone As First-Line (1L) Treatment for Advanced Squamous Non-Small Cell Lung Cancer (sq NSCLC) in Patients (pts) Who Were Smokers Vs Non-Smokers

1514P Randomized, Global, Phase III Study of Tislelizumab (TIS) + Chemotherapy (chemo) Vs Placebo (PBO) + Chemo As First-Line (1L) Treatment for Advanced/metastatic Esophageal Squamous Cell Carcinoma (ESCC): RATIONALE-306 Update

Tislelizumab Versus Chemotherapy As Second-Line Treatment for Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC, RATIONALE 302): Impact on Health-Related Quality of Life (Hrqol)

1263P Tislelizumab + Chemotherapy Vs Chemotherapy Alone As First-Line Treatment for Locally Advanced/metastatic Nonsquamous NSCLC

Perioperative Tislelizumab Plus Neoadjuvant Chemotherapy for Patients with Resectable Non-Small-cell Lung Cancer (RATIONALE-315): an Interim Analysis of a Randomised Clinical Trial

Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first line treatment for advanced gastric or gastro-oesophageal junction adenocarcinoma: RATIONALE-305 randomised, double blind, phase 3 trial

Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment for advanced or metastatic oesophageal squamous cell carcinoma (RATIONALE-306): a global, randomised, placebo-controlled, phase 3 study

The ICSH Reference Method for Serum Iron Assay: Recommendation for a Viable Automated Alternative

Results from RATIONALE 303: A global phase 3 study of tislelizumab (TIS) vs docetaxel (TAX) as second- or third-line therapy for patients with locally advanced or metastatic NSCLC.

1290P RATIONALE 304: Tislelizumab (TIS) Plus Chemotherapy (chemo) Vs Chemo Alone As First-Line (1L) Treatment for Non-Squamous (Non-Sq) Non-Small Cell Lung Cancer (NSCLC) in Patients (pts) Who Are Smokers Vs Non-Smokers

Randomized, phase 3 study of second-line tislelizumab versus chemotherapy in advanced or metastatic esophageal squamous cell carcinoma, RATIONALE 302: Asia subgroup.

Abstract CT039: Results from RATIONALE 303: A Global Phase 3 Study of Tislelizumab (TIS) Vs Docetaxel (TAX) As Second- or Third-Line Therapy for Patients with Locally Advanced or Metastatic NSCLC

Tislelizumab in Combination with Chemotherapy for the Treatment of Chinese Patients (pts) with Esophageal Squamous Cell Carcinoma (ESCC): Results from One Cohort of an Ongoing Phase 2 Study.

Randomized, phase 3 study of second-line tislelizumab vs chemotherapy in advanced or metastatic esophageal squamous cell carcinoma, RATIONALE 302: Asia subgroup.